UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Body composition and breast cancer risk and treatment: mechanisms and impact

Breast cancer research and treatment, 2021-04, Vol.186 (2), p.273-283

2021

Volltextzugriff (PDF)

Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer

Breast cancer research and treatment, 2020, Vol.179 (2), p.435-443

2020

Volltextzugriff (PDF)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

British journal of cancer, 2019-06, Vol.120 (12), p.1105-1112

2019

Volltextzugriff (PDF)

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review

PloS one, 2021-04, Vol.16 (4), p.e0250057-e0250057

2021

Volltextzugriff (PDF)

The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

Breast cancer research and treatment, 2020-10, Vol.183 (3), p.729-739

2020

Volltextzugriff (PDF)

Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC

BMC cancer, 2020-05, Vol.20 (1), p.430-9, Article 430

2020

Volltextzugriff (PDF)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Biomedicines, 2021-06, Vol.9 (7), p.740

2021

Volltextzugriff (PDF)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

Biomedicines, 2023-02, Vol.11 (3), p.735

2023

Volltextzugriff (PDF)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

Cancer medicine (Malden, MA), 2020-02, Vol.9 (3), p.1025-1032

2020

Volltextzugriff (PDF)

Advances in targets in inflammatory breast cancer

International review of cell and molecular biology, 2024, Vol.384, p.125-152

2024

Volltextzugriff (PDF)

Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape

Expert opinion on therapeutic targets, 2022-05, Vol.26 (5), p.405-425

2022

Volltextzugriff (PDF)

Abstract P5-07-03: Disease classification modeling of inflammatory breast cancer based on simultaneous profiling of coding and non-coding RNAs in tumor and blood samples by TGIRT-sequencing

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-07-03

2022

Volltextzugriff (PDF)

The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1056-1056

2020

Volltextzugriff (PDF)

The impact of quality and quantity of visceral fat on survival outcome of early-stage breast cancer patients with prior chemotherapy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.584-584

2017

Volltextzugriff (PDF)

Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3054-3054

2023

Volltextzugriff (PDF)

Correlation of micronuclei formation in circulating stromal cells with their PD-L1 expression and predicts for poorer clinical outcomes in metastatic breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14548-e14548

2023

Volltextzugriff (PDF)

Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3053-3053

2024

Volltextzugriff (PDF)

Abstract PS4-07: Identification of novel molecules that enhance neratinib efficacy in triple-negative breast cancer by high-throughput RNA interference

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS4-07-PS4-07

2021

Volltextzugriff (PDF)

Abstract PO4-23-11: Resistance Mechanisms to CDK4/6 Inhibitors and/or Tamoxifen Using Comprehensive Thermostable Group II Intron Reverse Transcriptase Sequencing

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO4-23-11-PO4-23-11

2024

Volltextzugriff (PDF)

Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients

Cancer medicine (Malden, MA), 2016-01, Vol.5 (1), p.41-48

2016

Volltextzugriff (PDF)

Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Clinical cancer research, 2024-06, p.OF1-OF9

2024

Volltextzugriff (PDF)

Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13632-e13632

2023

Volltextzugriff (PDF)

Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1105-1105

2023

Volltextzugriff (PDF)

Targeting Signaling Pathways in Inflammatory Breast Cancer

Cancers, 2020-09, Vol.12 (9), p.2479

2020

Volltextzugriff (PDF)

Elevated neutrophil to lymphocyte ratio to predict survival outcome after recurrence for patients with triple-negative breast cancer

Journal of clinical oncology, 2015-10, Vol.33 (28_suppl), p.24-24

2015

Volltextzugriff (PDF)

1 – 25 von 202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(177)

Publikationsform

Sprache

Englisch
(177)
Japanisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Body composition and breast cancer risk and treatment: mechanisms and impact

Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review

The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer

Advances in targets in inflammatory breast cancer

Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape

Abstract P5-07-03: Disease classification modeling of inflammatory breast cancer based on simultaneous profiling of coding and non-coding RNAs in tumor and blood samples by TGIRT-sequencing

The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC)

The impact of quality and quantity of visceral fat on survival outcome of early-stage breast cancer patients with prior chemotherapy

Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value

Correlation of micronuclei formation in circulating stromal cells with their PD-L1 expression and predicts for poorer clinical outcomes in metastatic breast cancer

Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes

Abstract PS4-07: Identification of novel molecules that enhance neratinib efficacy in triple-negative breast cancer by high-throughput RNA interference

Abstract PO4-23-11: Resistance Mechanisms to CDK4/6 Inhibitors and/or Tamoxifen Using Comprehensive Thermostable Group II Intron Reverse Transcriptase Sequencing

Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients

Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy

Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer

Targeting Signaling Pathways in Inflammatory Breast Cancer

Elevated neutrophil to lymphocyte ratio to predict survival outcome after recurrence for patients with triple-negative breast cancer

Suchergebnisse filtern